UK must reform drug pricing to become life sciences superpower, says GSK boss

Shares jump on higher profits as Emma Walmsley is hopeful' standoff with NHS can be resolved

GSK's outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a life sciences superpower" unless it overhauls drug pricing.

As ministers draw up proposals to increase the amount the NHS spends on new medicines by up to 25%, Walmsley said she was hopeful and ambitious" that the standoff with the pharma industry could be resolved.